MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI)(MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI))

概要

基本信息

药物类型

治疗性疫苗、树突状细胞疫苗

别名-

靶点

gp100 x melan-A

作用方式

调节剂

作用机制

gp100调节剂(黑素细胞蛋白PMEL调节剂)、melan-A调节剂(T细胞识别黑素瘤抗原调节剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

复发性黑色素瘤皮肤黑色素瘤转移性黑色素瘤

原研机构

National Cancer Institute

在研机构-

非在研机构

National Cancer Institute

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI) 相关的临床试验

NCT00019214

/ Completed临床1/2期IIT

Phase I/II Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From The Melanoma Associated Antigens MART-1 and gp 100

RATIONALE: Vaccines made from white blood cells treated with antigens may make the body build an immune response to kill melanoma cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may kill more melanoma cells.
PURPOSE: This phase I/II trial is studying the side effects and how well giving vaccine therapy and interleukin-2 works compared to vaccine therapy alone in treating patients with metastatic melanoma that has not responded to previous therapy.

开始日期1997-04-01

申办/合作机构

National Cancer Institute

NCT00019890

/ Completed临床2期IIT

Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely resected metastatic melanoma.

开始日期-

申办/合作机构

National Cancer Institute

100 项与 MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI) 相关的临床结果

登录后查看更多信息

100 项与 MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI) 相关的转化医学

登录后查看更多信息

100 项与 MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI) 相关的专利（医药）

登录后查看更多信息

100 项与 MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性黑色素瘤	临床2期	-	National Cancer Institute	2007-03-05
皮肤黑色素瘤	临床2期	美国	National Cancer Institute	1997-04-01
转移性黑色素瘤	临床2期	美国	National Cancer Institute	1997-04-01